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ABSTRACT:
Balance between pro-tumor and anti-tumor effects may be affected by molecular 
interactions within tumor microenvironment. On this basis we searched for molecular 
partners of ADAMTS-12, a secreted metalloprotease that shows both oncogenic and 
tumor-suppressive effects. Using its spacer region as a bait in a yeast two-hybrid 
screen, we identified fibulin-2 as a potential ADAMTS-12-interacting protein. Fibulins 
are components of basement membranes and elastic matrix fibers in connective 
tissue. Besides this structural function, fibulins also play crucial roles in different 
biological events, including tumorigenesis. To examine the functional consequences 
of the ADAMTS-12/fibulin-2 interaction, we performed different in vitro assays using 
two breast cancer cell lines: the poorly invasive MCF-7 and the highly invasive MDA-
MB-231. Overall our data indicate that this interaction promotes anti-tumor effects 
in breast cancer cells. To assess the in vivo relevance of this interaction, we induced 
tumors in nude mice using MCF-7 cells expressing both ADAMTS-12 and fibulin-2 that 
showed a remarkable growth deficiency. Additionally, we also found that ADAMTS-12 
may elicit pro-tumor effects in the absence of fibulin-2. Immunohistochemical staining 
of breast cancer samples allowed the detection of both ADAMTS-12 and fibulin-2 in 
the connective tissue surrounding tumor area in less aggressive carcinomas. However, 
both proteins are hardly detected in more aggressive tumors. These data and survival 
analysis plots of breast cancer patients suggest that concomitant detection of 
ADAMTS-12 and fibulin-2 could be a good prognosis marker in breast cancer diagnosis.
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INTRODUCTION
Extracellular matrix (ECM) components and 
their interactions are essential for homeostasis of 
tissues and provide structural support to animal cells 
[1-2]. These components also play crucial roles on cell 
dynamic behavior and act as modulators of intercellular 
communication [3-4]. Among them, fibulins family 
consists of seven secreted glycoproteins that share a 
globular domain at the carboxy-terminus, known as fibulin 
module, which is preceded by tandem calcium-binding 
Epithelial Growth Factor (cbEGF) domains [5-7]. Amino-
terminal region displays the highest structural variability. 
Functionally fibulins serve as a scaffold for different ECM 
components including proteoglycans [8], fibronectin [9], 
collagen [10], fibrillin [11] or laminin [12]. In addition to 
this structural role, fibulins can also participate in complex 
biological processes including cell migration, adhesion 
and proliferation [13], and mediate cell signaling events 
[14-15].
Fibulin-2 illustrates an example for the contribution 
of fibulins to those processes. In fact, fibulin-2 is 
recognized as a multifunctional binding protein due to its 
ability to bridge diverse ECM components [8, 16]. For 
instance, fibulin-2 participates in the assembling of the 
laminin network in the basement membrane through the 
binding of laminin-1 and laminin-5 to other matrix proteins 
[17]. Also, binding of nidogen to fibulin-2 contributes to 
the formation of ternary complexes with type IV collagen, 
perlecan and fibulin-1 [18]. Moreover, fibulin-2 promotes 
cell-ECM contacts by binding to β3 integrins [19]. These 
and other examples [16, 20] highlight the relevance of 
fibulin-2 in the maintenance of extracellular structures 
such as basement membranes, as well as contacts between 
cells and ECM. Complexity of functions of fibulin-2 is 
also evident in pathological conditions such as cancer [13, 
21]. In this regard, pro-tumor effects have been associated 
to this fibulin in pancreatic cancer cells as consequence of 
its interaction with the transmembrane type I glycoprotein 
MUC4 [22]. However, a growing number of studies 
point out the anti-tumor properties of fibulin-2. For 
instance, this fibulin acts as an anti-angiogenic factor in 
nasopharyngeal carcinoma [23]; FBLN2, the human gene 
coding for fibulin-2, is found epigenetically silenced in 
B cell acute lymphoblastic leukemia [24]; and loss of 
fibulin-2 expression facilitates tumor progression in breast 
cancer cells [25]. These findings reveal the importance 
of fibulin-2 in tumor development. Nonetheless, the 
molecular mechanism by which this fibulin promotes or 
inhibits tumorigenesis is unclear at present. 
ADAMTS-12 is a secreted metalloprotease [26] 
and different studies have suggested a role for this 
metalloprotease in tissue remodeling and cell migration 
or adhesion [27-28]. Moreover, ADAMTS-12 acts 
as a tumor-suppressor enzyme. Thus, this enzyme 
hinders anti-tumor effects in Madin-Darby canine 
kidney (MDCK) cells treated with hepatocyte growth 
factor [29]. Furthermore, ADAMTS12 gene promoter is 
hypermethylated in colorectal carcinomas [30]. Phenotypic 
analysis of the Adamts12-deficient mouse has confirmed 
the tumor-protective role of this enzyme [31]. By contrast, 
ADAMTS-12 has been also associated to trophoblastic 
cell invasion by modulating the expression and function 
of αvβ3 integrin [32]. Exploring the mechanisms that link 
ADAMTS-12 to tumorigenesis would help to minimize 
pro-tumor properties and thereby enhance anti-tumor 
effects of this metalloprotease.
Here we show that ADAMTS-12 and fibulin-2 are 
two interacting proteins. Functional consequences of 
this interaction were evaluated using different cell-based 
assays. Two breast cancer cell lines, MCF-7 and MDA-
MB-231, were employed attending to the anti-tumor role 
of fibulin-2 [25] and expression profile of ADAMTS12 [33] 
in this type of tumor. Immunohistochemical detection of 
fibulin-2 and ADAMTS-12 was also performed using a 
human breast cancer tissue array. Main conclusion is that 
ADAMTS-12/fibulin-2 interaction potentiates anti-tumor 
effects in breast cancer cells. 
RESULTS
ADAMTS-12 and fibulin-2 are two interacting 
proteins 
Different fragments corresponding to the 
ADAMTS-12 exosites, including thrombospondins and 
spacer regions, were employed as baits to screen for 
molecular partners of the metalloprotease using yeast two-
hybrid assays. Among them, a fragment corresponding 
to spacer-1 allowed to select different clones containing 
inserts that according to BLAST analysis at NCBI (www.
ncbi.nlm.nih.gov) matched with extracellular matrix 
proteins such as NELL2, connective tissue growth factor 
or agrin. Interestingly, one of these clones, with a 630-
bp insert, corresponded to nucleotides 3360 to 3990 of 
human fibulin-2 cDNA (GenBankTM accession number 
X82494.1). Conceptual translation of this region showed 
that the sequence matched with the carboxyl-end region 
of fibulin-2, including the final 88 amino acids of the 
fibulin module (Fig.1A). Taking in account that an 
interaction between fibulin-1 and ADAMTS-1 had been 
previously described [34], we decided to explore the 
functional consequences of a new interaction between 
an ADAMTS metalloprotease and a fibulin. As a first 
approach to validate this interaction we examined a 
potential co-immunoprecipitation of both proteins. To 
this end, we employed 293-EBNA cell extracts containing 
ADAMTS-12 tagged with a FLAG epitope. Different 
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amounts of fibulin-2 were added to these extracts and 
immunoprecipitation was performed using an anti-FLAG 
M2 affinity gel. Immunoprecipitates were visualized by 
Western blot using an anti-fibulin-2 antibody (Fig. 1B). 
An immunoreactive band corresponding to fibulin-2 was 
detected in those cell extracts containing ADAMTS-12 
incubated with the fibulin. However this band was not 
detected without incubation with fibulin-2 or when the 
same immunoprecipitation procedure was applied to 
extracts of EBNA control cells (EBNAc) (Fig. 1B). 
Conversely, cell extracts were also immunoprecipitated 
with an anti-fibulin-2 antibody and immunoblotted with 
an anti-FLAG antibody. In this case, an immunoreactive 
band corresponding to ADAMTS-12 was detected in two 
samples containing fibulin-2, but not in control samples 
(Fig. 1B). These results strongly suggest that fibulin-2 
physically binds to ADAMTS-12. Considering this, 
we decided to examine whether fibulin-2 could act as a 
cofactor for the metalloprotease, similarly to what occurs 
with fibulin-1 and ADAMTS-1 [34]. However, presence 
Figure 1: ADAMTS-12 and fibulin-2 are two interacting 
proteins. (A) Schematic illustration of the interacting regions 
between ADAMTS-12 and fibulin-2 determined by yeast two-
hybrid screen. TSP-1, thrombospondin-1-like domain; Cys-
rich domain, cysteine-rich domain; PLAC, protease-lacunin; 
RGD, Arginine-Glycine-Aspartic Acid; EGF, ephitelial 
growth factor; CB-EGF, Calcium-binding EGF; BD, binding 
domain; AD, activating domain. (B) Western blot analysis 
of immunoprecipitated samples. Top, 293-EBNA control 
cells extracts (EBNAc) or 293-EBNA cell extracts producing 
ADAMTS-12-FLAG (EBNA-ADAMTS-12) were incubated 
with the indicated amounts of fibulin-2, immunoprecipitated 
with using anti-FLAG M2 affinity gel and further detection was 
performed with an anti-fibulin-2 antibody. Bottom, cell extracts 
were immunoprecipitated with an anti-fibulin-2 antibody and 
detection was performed with an anti-ADAMTS-12 antibody. 
F indicates that 1 µg of fibulin-2 was loaded in these lanes. 
Molecular weight marker is indicated on the right.
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of fibulin-2 did not increase the low aggrecanase activity 
of ADAMTS-12 using a peptide corresponding to the 
aggrecan IGD domain as substrate (Supplementary Fig. 
S1). 
Interaction between fibulin-2 and ADAMTS-12 
reduces breast cancer cell invasion and migration.
Next, we wanted to assess the functional 
consequences of the interaction between ADAMTS-12 and 
fibulin-2. To this end, we transfected MCF-7 and MDA-
MB-231 cells with the full-length cDNAs for ADAMTS12 
and FBLN2. Production of recombinant fibulin-2 (fb), 
ADAMTS-12 (ts) or both proteins simultaneously (fb/ts) 
was analyzed by Western blot (Fig. 2A and supplementary 
Fig. S2). Prior to functional analysis, we proved that 
presence of these extracellular proteins did not affect 
cell proliferation (Supplementary Fig. S3), and that the 
interaction between fibulin-2 and ADAMTS-12 also took 
place in MCF-7-(fb/ts) cells (Fig. 2B). Then, to analyze the 
role of this interaction in cell invasion, cells were allowed 
to invade using Matrigel-coated invasion chambers (Fig. 
2C). This assay showed that both MCF-7-(fb/ts) and 
MDA-MB-231-(fb/ts) cells exhibited a very low invasive 
potential in comparison with control cells (63 %, and 76 
% reduction respectively), or with cells producing only 
fibulin-2 (58 % and 47 % reduction). Similarly to what has 
been previously reported [25], the highly invasive MDA-
MB-231 cell line producing fibulin-2, MDA-MB-231-
(fb), remarkably reduced its invasive potential comparing 
to control cells (55 % reduction, Fig. 2C). However, in 
the case of the poorly invasive MCF-7 no differences 
were observed between control and MCF-7-(fb) cells. By 
contrast, both MDA-MB-231-(ts) and MCF-7-(ts) showed 
a higher invasive ability than MDA-MB-231-(fb) and 
MCF-7-(fb) respectively (Fig. 2C).
Interaction between fibulin-2 and ADAMTS-12 also 
affected cell migration. As can be seen in Fig. 3A, MCF-
7-(fb/ts) cells did not show differences (37 % covered 
area) respecting MCF-7-(ts) (39 %), MCF-7-(fb) (37 %) 
or control cells (37 %) when migration was evaluated after 
24 h using uncoated wells (supplementary videos 1 to 4). 
Figures 3: Interaction between fibulin-2 and 
ADAMTS-12 hinders migration of MCF-7 cells on 
ECM components. (A) MCF-7-(fb) (fibulin-2), MCF-7-(ts) 
(ADAMTS-12), and MCF-7-(fb/ts) (ADAMTS-12/fibulin-2) 
were allowed to migrate in uncoated wells or wells coated with 
type-I collagen, fibronectin or laminin I. MCF-7 cells transfected 
with an empty vector were used as control. Pictures of starting 
(t=0 h) and final (t=24 h) times are included. Starting point is 
indicated with a thin dotted line and final point with a thick 
dotted line. (B) Graphical representation of covered area after 
24 h from three independent experiments.
Figure 4: Simultaneous production of fibulin-2 and 
ADAMTS-12 reduces self-renewal of mammosphere-
forming units in MCF-7 cells. (A) Representative images of 
mammospheres derived from MCF-7-(fb) (fibulin-2), MCF-7-(ts) 
(ADAMTS-12), and MCF-7-(fb/ts) (ADAMTS-12/fibulin-2). 
Control, MCF-7 cells transfected with an empty vector. Sizes 
of some mammospheres are indicated. (B) Mammospheres were 
dissociated and passaged at a density of 20 cell/well in 96-well 
plates, and MFUs were counted and calculated as a percentage 
of mammospheres formed from the number of cell seeded. 
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However, a significant reduction in migratory capacity of 
MCF-7-(fb/ts) cells was observed when these cells were 
grown in wells coated with fibronectin, laminin I, or type-I 
collagen (supplementary videos 5 to 8). Thus, 35 % and 
37 % of area was covered by MCF-7-(fb/ts) cells in wells 
coated with type-I collagen and fibronectin, respectively. 
Nonetheless, MCF-7-(ts), MCF-7-(fb) and control cells 
covered 91 %, 70 % and 71 % on type-I collagen, and 75 
%, 62 % and 70 % on fibronectin respectively. In the case 
of laminin I, MCF-7-(fb/ts) cells covered 54 % whereas 
MCF-7-(ts), MCF-7-(fb) and control cells covered around 
85 % (Fig. 3B). Similar experiments performed with 
MDA-MB-231 cells revealed that fibulin-2/ADAMTS-12 
interaction also hindered the ability of these cells to 
migrate, but differences were not so pronounced between 
MDA-MB-231-(fb) and MDA-MB-231-(fb/ts) as in MCF-
7 cells (Supplementary Fig. S4). Altogether, these data 
support that ADAMTS-12 fibulin-2/ interaction hampers 
both invasion and migration of breast cancer cells in vitro, 
but also that ADAMTS-12 could exert pro-tumor effects 
in the absence of fibulin-2.
Combined expression of FBLN2 and ADAMTS12 
reduces mammosphere formation 
3D culture system mimics the natural tissue 
environment of the cell. In the case of breast cancer 
cells, this culture system allows mammosphere formation 
and reflects the ability of these cells for in vitro self-
renewal. Therefore we examined whether ADAMTS-12 
and fibulin-2 could also alter the mammosphere-forming 
ability of breast cancer cells. To this end, 4 x 104  MCF-
7 cells were plated in 6-well plates and mammospheres 
were visualized after 7 days. MCF-7-(fb/ts) showed a 
smaller number and mammospheres size than MCF-7-(fb), 
MCF-7-(ts) or MCF-7 control cells (Fig. 4A and 4B). To 
quantify the mammosphere forming units (MFUs), cells 
were dissociated using trypsin and passaged at a density 
of 20 cells/well through a 96-well plate. 7 days later, 
MFUs were calculated and MCF-7-(fb/ts) showed 3.2-
fold decrease of MFUs compared to MCF-7 control cells, 
and 2-fold decrease compared to MCF-7-(fb) and MCF-
7-(ts) cells (Fig. 4B). In the case of MDA-MB-231 cells, 
exogenous expression of ADAMTS-12 and fibulin-2 also 
caused a decrease in MFUs compared to MDA-MB-231-
(ts) cells (2-fold) and to MDA-MB-231 control cells (2.5-
fold). However, difference between MDA-MB-231-(fb/ts) 
and MDA-MB-231-(fb) was slight (Supplementary Fig. 
S5A and S5B). Overall, these results indicate that fibulin-2 
and ADAMTS-12 affect ability of breast cancer cells to 
form mammospheres. 
Interaction between fibulin-2 and ADAMTS-12 
inhibits tumor growth in vivo
To evaluate the effect of ADAMTS12 and FBLN2 
expression in vivo, MCF-7-(fb), MCF-7-(ts) or MCF-
7-(fb/ts) cells were subcutaneously injected in the flank 
of nude mice. Control MCF-7 cells were injected in the 
opposite flank and the evolution of tumor growth was 
followed by 6 weeks. MCF-7-(fb/ts) cells displayed a 
significantly reduced tumor growth rate when comparing 
to MCF-7-(fb), MCF-7-(ts) or MCF-7 control cells (Fig. 
5). Thus, at the time of sacrifice, tumor volume derived 
from MCF-7-(fb/ts) cells was, on average, 25 % smaller 
than those derived from MCF-7-(fb) and MCF-7 control 
cells, and 90 % smaller than those derived from MCF-
7-(ts) cells. These results indicate that the interaction 
between fibulin-2 and ADAMTS-12 may also promote 
anti-tumor effects in vivo.
Inverse correlation of ADAMTS12 and FBLN2 
expression with breast cancer stage
To determine clinical relevance of ADAMTS-12 
and fibulin-2 in breast cancer, we performed an 
immunohistochemical analysis of a tissue array containing 
16 samples of normal and breast cancer tissues. A strong 
Figure 5: Presence of fibulin-2 and ADAMTS-12 inhibits growth of subcutaneous tumors. (A) Nude mice were injected 
with MCF-7-(fb) (fibulin-2), MCF-7-(ts) (ADAMTS-12), MCF-7-(fb/ts) (ADAMTS-12/fibulin-2) or control MCF-7 cells, and tumors 
growth were weekly measured. (B) Representative subcutaneous tumors at the time of sacrifice (6 weeks).
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staining for fibulin-2 was mainly detected in periductal 
connective tissue in normal breast (Fig. 6A). ADAMTS-12 
was also detected in epithelia duct cells but showing a 
weaker staining. A moderate to strong expression of both 
fibulin-2 and ADAMTS-12 was detected in connective 
tissue surrounding tumor in grade 1 or 1 to 2 breast 
carcinoma (n=5). However, weak or absent staining was 
observed in 10 out 11 (91 %) samples of grade 2 and 3 
breast carcinoma for both fibulin-2 and ADAMTS-12. 
These data point to an inverse correlation between FBLN2 
and ADAMTS12 co-expression and histophatological 
tumor grade. 
We next assessed the association between 
ADAMTS12 and FBLN2 expression with clinical outcome 
using data available at www.kmplot.com. Kaplan-Meier 
curves revealed that a combined high expression of 
both ADAMTS12 and FBLN2 correlated with the best 
prognosis in breast cancer patients (Hts+Hfb, Fig. 6B) 
when compared to patients expressing low levels of both 
genes (Lts+Lfb) (p < 0.001). This analysis also showed 
that simultaneous high ADAMTS12 and low FBLN2 
expressions (Hts+Lfb) associated to better outcome. 
However, high expression levels of FBLN2 combined 
with a low expression of ADAMTS12 (Lts+Hfb) showed 
Figure 6: FBLN2 and ADAMTS12 expression analysis in breast cancer samples. (A) representative tissue images for detection 
of ADAMTS-12 and fibulin-2 in healthy breast tissue and breast carcinoma samples. Arrows indicate detection of ADAMTS-12 and 
fibulin-2 in grade 1 breast carcinoma. Scale bar, 200 µm. (B) Kaplan-Meier survival plots showing a better outcome of breast patients with 
high expression level of both ADAMTS12 and FBLN2 (Hts+Hfb). Plots for high ADAMTS12 and low FBLN2 (Hts+Lfb); low ADAMTS12 
and high FBLN2 (Lts+Hfb); and low ADAMTS12 and low FBLN2 (Lts+Lfb) are also included.
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a slight but not significant increase of survival rate (Fig. 
6B). These data suggests that factors other than combined 
expression of these two genes could modulate the pro or 
anti-tumor activities of both fibulin-2 and ADAMTS-12.
DISCUSSION
ECM regulates almost all cellular behavior and 
multiple regulatory mechanisms to ensure that production 
and remodeling of ECM components are normal during 
organ development [1, 35]. Altered ECM can trigger 
cell signals or molecular interactions that promote cell 
survival or proliferation thereby contributing to cancer 
development [36]. Hence a major challenge in ECM 
biology is to understand the role of its components in 
normal and pathological processes. In this regard, a 
growing number of studies emphasize the multiple roles 
of fibulins in development and homeostasis of tissues 
[16]. Beyond this structural role, both tumor-suppressive 
functions and oncogenic activities have also been related 
to these glycoproteins [21]. Diverse mechanisms may 
underlie these apparently contradictory roles in cancer, 
including their interactions with other extracellular matrix 
components [13].
In the present work, using a yeast two-hybrid 
screening, we have found that fibulin-2 is a new partner 
of the ADAMTS-12 metalloprotease. Interaction 
between these two secreted proteins was confirmed 
by co-immunoprecipitation. Functional consequences 
of this interaction were evaluated by different cell-
based assays using two human breast cancer cell lines, 
the poorly invasive MCF-7 and the highly invasive 
MDA-MB-231. None of them express fibulin-2 [25] or 
ADAMTS-12 endogenously [30-31], hence we have 
selected clones producing ADAMTS-12, fibulin-2 or 
both proteins simultaneously. Exogenous expression of 
these proteins did not alter cell growth rates. However, 
results obtained from other cell-based assays point to two 
important findings. First, anti-tumor properties associated 
to fibulin-2 in breast cancer [25] are enhanced by its 
interaction with ADAMTS-12, especially in MCF-7 cells. 
Thus, production of both proteins remarkably reduced 
MCF-7 cells ability to invade in Matrigel-coated invasion 
chambers. This interaction also decreased the percentage 
of mammosphere-forming units, and strongly inhibited 
cell migration on fibronectin or laminin, two extracellular 
matrix components that associate to fibulin-2 [17]. 
Additionally, MCF-7-(fb/ts) cells displayed a reduced 
tumor growth when were subcutaneosuly injected in the 
flank of nude mice. Data obtained using MDA-MB-231 
cells indicated that differences were less marked between 
MDA-MB-231-(fb/ts) and MDA-MB-231-(fb). In this 
regard, it has been previously found that pro-tumor 
properties of MDA-MB-231 cells are especially hampered 
by fibulin-2. In fact, exogenous expression of fibulin-2 
in this cell line reduced speed of wound-healing closure 
and decreased cell invasion in vitro [25]. Moreover, 
fibronectin-induced migration of MDA-MB-231 cells is 
markedly inhibited by fibulin-1 [37], the closest molecular 
partner of fibulin-2. Consequently, both fibulin-1 and -2 
may inhibit oncogenic properties of breast cancer cells. 
Mechanisms underlying these effects are not yet known, 
but association with other ECM components could also 
influence pro-tumor or anti-tumor activities of fibulins.
The second relevant finding is that ADAMTS-12 
could promote pro-tumor properties when is produced in 
breast cancer cells in the absence of fibulin-2. Exogenous 
expression of the metalloprotease not only increased 
invasion and migration capacities of MCF-7 cells in vitro 
but also produced significantly higher tumor volumes in 
nude mice. Contrary to this, we had previously found 
that exogenous expression of ADAMTS12 in A549 cells 
inhibited tumor growth in vivo [29]. An explanation for 
these apparent contradictory results is that A549 cells 
express fibulin-2 [14]. Thus, it can be speculated that 
exogenous ADAMTS-12 may interact with fibulin-2 
produced by A549 cells and thereby inducing the anti-
tumor effect observed. A previous report also supported 
the pro-tumor activity of this metalloprotease since its 
exogenous expression potentiated invasive capacity of 
the human placental choriocarcinoma cell line JEG-
3 [32]. Moreover, exogenous ADAMTS-12 reduced 
the ability of JEG-3 cells to bind to collagen-1 and our 
data indicate that presence of ADAMTS-12 increases 
migration on collagen-1 of MCF-7 cells. Interestingly, an 
enhanced stromal collagen-1 deposition correlates with 
breast cancer metastasis [38]. In this scenario and in the 
absence of fibulin-2, ADAMTS-12 could contribute to 
tumor progression by increasing the migratory capacity 
of breast tumor cells on collagen-1. By contrast, several 
studies have highlighted the anti-tumor role of this 
metalloprotease, including the phenotypic characterization 
of Adamts12-deficient mouse [31]. Different mechanisms 
may cause the anti-tumor effects of ADAMTS-12. For 
instance, thrombospondin type-1 motifs at carboxy-
terminal region of the protease influence its antimetastatic 
potential. However this enzyme undergoes proteolytic 
processing events that could modify this effect [29]. Some 
of these properties resemble those previously described 
for ADAMTS-1. Thus, this metalloprotease was initially 
catalogued as a tumor-suppressor factor due to the angio-
inhibitory properties related to the thrombospondin type-
1 domains located at the carboxy-terminal region [39]. 
Furthermore, a decreased expression of ADAMTS-1 
in breast cancer favors breast cancer migration and 
invasion [40]. Nonetheless, ADAMTS-1 can also 
generate anti-angiogenic peptides through the digestion 
of thrombospondin-1[41] or endorse the recruitment 
of fibroblasts involved in tumor growth, an effect also 
associated to an increased deposition of collagen-1 [42]. 
Moreover, ADAMTS-1 interacts with other member of 
the fibulin family, fibulin-1 [34], which in this case acts 
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as a cofactor of the metalloprotease. Hence, fibulin-1 
could potentiate degradation of ECM components by 
ADAMTS-1 and thereby facilitating tumor progression. 
We explored the possibility that fibulin-2 could be a 
regulatory factor of the metalloprotease activity. Given 
that ADAMTS-12 displays low aggrecanase activity 
in vitro [29], we evaluated the digestion of a peptide 
corresponding to the human aggrecan interglobular 
domain. However, our results indicated that the presence 
of fibulin-2 did not potentiate the cleavage of this peptide 
by ADAMTS-12. Despite of this, it cannot be ruled out 
that this fibulin could act as an enhancer or inhibitor of 
ADAMTS-12 enzymatic activity in other circumstances 
considering the limited number of known in vivo 
substrates for this enzyme.
Immunohistochemical staining revealed that 
ADAMTS-12 was mainly detected in the stroma of grade 
1 breast carcinomas, similar to what had been previously 
reported in colorectal cancer [30]. Staining pattern of 
fibulin-2 showed an equivalent situation. However, both 
proteins are hardly detected in grade 2 and 3 breast 
carcinomas. Thus, it can be speculated that a potential 
interaction between these two proteins may happen in less 
aggressive breast cancers and that this interaction could 
form part of a stromal response aimed to block cancer 
progression. Kaplan-Meier survival plots also suggested a 
potential tumor-suppressive role of the concomitant high 
expression of both ADAMTS12 and FBLN2. However, 
some results of this work also suggest a pro-tumor 
activity of ADAMTS-12 in the absence of fibulin-2. In 
consequence, pro or anti-tumor activities of ADAMTS-12 
could also be influenced by factors other than interaction 
with fibulin-2.
Interaction between ADAMTSs and fibulins 
raises new questions about the role of these proteins in 
tumor progression. For instance, these interactions may 
underlie the molecular mechanisms by which some 
tumor-protective metalloproteases exert their anti-tumor 
activities. In this work we show that ADAMTS-12/
fibulin-2 interaction induces anti-tumor effects in breast 
cancer cells and our data also suggest that combined 
detection of both proteins could be a good prognosis 
marker in breast cancer patients. Further exhaustive 
functional and mechanistic studies will help finding 
out the precise role of ADAMTS-12 and fibulin-2 in 
relation to tumorigenesis, including the importance of 
the ADAMTS-12/fibulin-2 molar ratio as an indicator of 
potential invasiveness of breast cancer cells. Additionally, 
tumor susceptibility assays using mice lacking both 
Adamts12 and Fbln2 genes would be necessary to 
understand in depth the significance of this interaction 
not only in breast cancer but also in tumors from different 
origins. 
MATERIALS AND METHODS
Yeast Two-hybrid Screening
The Matchmaker Two-hybrid System and a human 
fetal kidney library (prey vectors) containing a sequence 
enconding amino acids 768-881 of the GAL4 protein (AD) 
were purchased from Clontech. Screening process was 
performed following manufacturer´s recommendations. 
Briefly, a cDNA fragment encoding amino acids 702-
813 of human ADAMTS-12 (GenBankTM accession 
number AAI31734) was PCR amplified using the primers 
5´-AAACATATGCAGACTGTGAGAAAGAT GTT-
3´ and 5´-TATGTCGACTGGATTGTGTACTCATA 
CTT-3´and inserted between the NdeI and SalI sites of 
the pGBKT7 vector to make a bait vector encoding a 
GAL4-BD-ADAMTS-12702-813 chimeric protein. Both bait 
and prey vectors were introduced into Saccharomyces 
cerevisiae AH109 cells and selection of double 
transformants was performed on synthetic minimal 
medium lacking leucine, tryptophan and histidine. 
Colonies were restreaked, and prey plasmids rescued, 
transfected into Escherichia coli DH5α and selected on LB 
medium containing 100 μg/mL ampicillin. Identification 
of the prey inserts was performed by direct sequencing.
Human cell lines, plasmids and transfection
MCF-7 and MDA-MB-231 breast cancer cells, 
obtained from ATCC, and 293-EBNA cells producing 
exogenous ADAMTS-12 containing a FLAG epitope [29] 
were routinely maintained in DMEM medium containing 
10 % heat-inactivated fetal bovine serum and 100 U/
mL penicillin and 50 µg/mL streptomycin. pCEP-TS12 
vector [29] and the full-length cDNA clon HK9 [8] were 
employed to overproduce ADAMTS-12 and human 
fibulin-2 respectively. These vectors were transfected into 
MCF-7 and MDA-MB-231 cells using Lipofectamine 
reagent (Life Technologies) as recommended by the 
manufacturer. Recombinant ADAMTS-12 and fibulin-2 
were obtained as previously described [8, 29]. Cells 
stably expressing ADAMTS12 (ts), FBLN2 (fb) or both 
simultaneously (fb/ts), or transfected with an empty vector 
were selected in the presence of 1.5 µg/mL puromycin 
(Sigma-Aldrich).
Western blotting and immunoprecipitation
For western blot analysis, proteins were resolved by 
8 or 12 % polyacrylamide gel electrophoresis, transferred 
to a nitrocellulose membrane and subsequently probed 
with the indicated antibodies. Primary antibodies used 
for detection of ADAMTS-12 were H-142 (Santa 
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Cruz Biotech) or anti-FLAG-M2 (Sigma-Aldrich), 
and for detection of fibulin-2 was H-250 (Santa Cruz 
Biotech). Anti-actin antibody was from Sigma-Aldrich. 
Immunoreactive proteins were visualized using HRP-
peroxidase labeled anti-rabbit or anti-mouse secondary 
antibody and the ECL detection system (Pierce). Relative 
expression levels were quantified and normalized to 
actin levels within the same blot using the Image J 
software. For immunoprecipitation, MCF-7-(fb/ts) were 
resuspended in lysis buffer (20 mM Tris-HCl pH 8.0, 
150 mM NaCl, 5 mM iodoacetamide, 0.5 mM CaCl2, 
0.5 mM MgCl2, 0.02 % NaN3, 1mM AEBSF and 1 % 
Triton X-100), containing one complete protease inhibitor 
cocktail tablet (Roche Molecular Biochemicals) per 50 
mL buffer. Protein concentration was quantified using 
the BCA Protein Assay Kit from Pierce Technology. 
To immunoprecipite ADAMTS-12, cell extracts were 
incubated with anti-FLAG M2 affinity gel (Sigma-
Aldrich) following manufacturer´s instructions. To 
immunoprecipitate fibulin-2, we used H-250 antibody and 
the Protein G Immunoprecipitation kit (Sigma-Aldrich), 
following manufacturer´s instructions. MCF-7 cells 
extract producing fibulin-2 was used as a negative control. 
In the case of EBNA-293 cells producing ADAMTS-12, 
cell extracts were incubated with the indicated amounts 
of fibulin-2 prior to the immunoprecipitation step. EBNA 
cells transfected with an empty vector (EBNAc) were used 
as negative control. 
Enzyme activity
ADAMTS-12 enzymatic activity was evaluated 
using a 10xHis tagged peptide corresponding to the 
interglobular (IGD) domain of aggrecan as substrate at 
0.016 µg/µl (rhAggrecan G1-IGD-G2, R&D Systems). 
As indicated, different amounts of fibulin-2 were added 
to the reaction. Reactions were performed in 20 µL for 4 
hours in the buffer previously described [29]. Degradation 
by ADAMTS-4 (R&D Systems) was employed as positive 
control. Peptide degradation was examined by western 
blot using an anti-His antibody (Quiagen).
Cell proliferation
Cell proliferation was measured using the CellTiter 
96 Non-radiactive Cell Proliferation Assay kit purchased 
from Promega. 103 cells were seeded in 96-well plates and 
six replicates per condition and time point were assessed. 
Cell proliferation rates were determined on three (MCF-
7) or four (MDA-MB-231) consecutive days using an 
automated microtiter plate reader Power Wave WS 
(BioTek).
Invasion assays
In vitro invasion potential was evaluated using 24-
well Matrigel-coated invasion chambers with a 8 µm pore 
size (BD Biosciences). For MCF-7 cells, 2.5 x 104 cells 
were allowed to migrate for 96 h using 10 % foetal bovine 
serum as a chemoattractant. Cells that reached the lower 
surface were stained with crystal violet. At least three 
independent experiments were performed with triplicates 
for each condition. Cells were counted in eight randomly 
selected microscopic fields. In the case of MDA-MB-231 
cells, invasion was evaluated after 24 h.
Migration assays
Migratory capacity of cells on ECM components 
fibronectin, laminin I, and type-I collagen was examined 
using the RadiusTM 24-Well Cell Migration Assay kit (Cell 
Biolabs) following manufacturer’s instructions. Briefly, 
1,25 x 104 cells were seeded per well and migration was 
monitored by time-lapse microscopy using a Zeiss Axio 
Observer Microscopy. Experiments were performed with 
triplicates and covered area was quantified at different 
times using Image J. Results were obtained after 24 h 
migration for MCF-7 cells and after 6 h for MDA-MB-231 
cells.
Mammospheres culture
4 x 104 MCF-7 or 5 x 103 MDA-MB-231 cells 
were plated in 6-well ultralow attachment plates (Costar) 
and grown in MammoCult Basal Medium (Stem 
Cell Research) supplemented with 10 % Mammocult 
Proliferation Supplement, 4 µg/mL heparine and 0.5 µg/
mL hydrocortisone. After 7 days, mammospheres were 
collected and enzymatically dissociated as previously 
described [43]. Individual dissociated cells were cultured 
in 96-well ultralow attachment plates at a density of 20 
cells/well. Mammospheres formation was monitored 
microscopically daily to ensure they derived from single 
cells and not from aggregates. Number of mammospheres 
was determined after 7 days culture. 
Animals and subcutaneous tumors
Four to five-week-old female athymic nude mice 
(nu/nu Swiss mice from Charles River Laboratories) were 
used for in vivo studies. To induce subcutaneous tumors, 
three groups of five mice were injected at one flank with 
7 x 106 cells of MCF-7-(fb), MCF-7-(ts) or MCF-7-(fb/
ts) cells in 200 µL PBS. As a control, the opposite flank in 
each animal was injected with identical number of control 
MCF-7 cells transfected with an empty vector. Tumor 
growth was monitored weekly as previously described 
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[29]. For estrogen supplementation, pellets of 1.5 mg 
17-β-estradiol, 90-day release (Innovative Research 
of America), were implanted between the scapulae at 
the time of injection. Mice were housed under specific 
pathogen-free conditions and following the guidelines 
of the Committee on Animal Experimentation of the 
Universidad de Oviedo, Asturias, Spain. 
Human breast cancer tissue array
A breast cancer tissue array containing 16 tumors 
samples from different tumor stages (Acris Antibodies) 
was employed to evaluate ADAMTS12 and FBLN2 
expression in human breast samples. Slides were 
processed for indirect peroxidase immunohistochemistry 
in the following way: sections were deparaffinized and 
rehydrated, and then rinsed in phosphate buffered saline 
(PBS) containing 1 % tween-20. For detection of fibulin-2 
(H-250 antibody) and ADAMTS-12 (H-142 antibody), 
sections were heated in high pH Envision FLEX target 
retrieval solution at 80 °C for 20 min and then incubated 
for 20 min at room temperature in the same solution. 
Endogenous peroxidase activity (3 % H2O2) and non-
specific binding (33 % fetal calf serum) were blocked 
and the sections were incubated overnight at 4 °C with 
primary antibodies described above using a 1:100 
dilution for both antibodies. As secondary antibodies we 
used labelled polymer-HRP ready to use from DAKO. 
3-3’ diaminobenzidine was employed as a chromogen. 
Selected slides were counterstained with haematoxylin. 
The intensity of immunostaining was evaluated by two 
independent observers directly upon microscope and 
was scored as absent, slight, moderate and strong. Study 
methodologies were conformed to the standards set by the 
Declaration of Helsinki and were approved by the Ethics 
Committee of the Universidad de Oviedo-Principado de 
Asturias (Spain). 
Survival analysis
To assess the effect of ADAMTS-12 and fibulin-2 
on breast cancer prognosis, survival probability was 
determined using the data available at www.kmplot.com 
[44]. 1592 patients were selected and we compared high 
(top 25 % of patients) and low (bottom 25 % of patients) 
expression of ADAMTS12, FBLN2 and both genes 
simultaneously. Results were represented as Kaplan-Meier 
long-rank test survival plots.
Statistical analysis
Statistical analysis were carried out using the 
GraphPad Prism 5.0 Software. Data were represented as 
means +/- S.E. The occurrence of significant differences 
was determined with the Student-Welch t test. p values 
under 0.05 were considered statistically significant (p < 
0.05, *; p < 0.01, **; p < 0.005, ***).
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